Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Income from Continuing Operations (2016 - 2026)

Perspective Therapeutics' Income from Continuing Operations history spans 17 years, with the latest figure at 26189000.0 for Q1 2026.

  • On a quarterly basis, Income from Continuing Operations fell 44.08% to 26189000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 8012000.0, a 90.72% increase, with the full-year FY2024 number at 79989000.0, down 99.44% from a year prior.
  • Income from Continuing Operations hit 26189000.0 in Q1 2026 for Perspective Therapeutics, down from 66145000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for CATX hit a ceiling of 66145000.0 in Q4 2025 and a floor of 41828000.0 in Q4 2024.
  • Historically, Income from Continuing Operations has averaged 9477176.47 across 5 years, with a median of 11214000.0 in 2024.
  • Biggest five-year swings in Income from Continuing Operations: tumbled 3087.33% in 2024 and later soared 258.14% in 2025.
  • Tracing CATX's Income from Continuing Operations over 5 years: stood at 7335000.0 in 2022, then plummeted by 149.12% to 18273000.0 in 2023, then plummeted by 128.91% to 41828000.0 in 2024, then soared by 258.14% to 66145000.0 in 2025, then plummeted by 139.59% to 26189000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for CATX at 26189000.0 in Q1 2026, 66145000.0 in Q4 2025, and 25969000.0 in Q3 2025.